Oppenheimer & Co. Inc. Has $2.24 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Oppenheimer & Co. Inc. increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 20.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 6,248 shares of the biotechnology company’s stock after purchasing an additional 1,078 shares during the period. Oppenheimer & Co. Inc.’s holdings in United Therapeutics were worth $2,239,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in UTHR. LSV Asset Management lifted its holdings in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after acquiring an additional 436,851 shares during the last quarter. Swedbank AB bought a new position in United Therapeutics in the 1st quarter valued at approximately $97,316,000. Canada Pension Plan Investment Board boosted its position in United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after buying an additional 153,700 shares in the last quarter. Assetmark Inc. grew its stake in shares of United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after buying an additional 152,249 shares during the last quarter. Finally, Pacer Advisors Inc. increased its holdings in shares of United Therapeutics by 19.6% during the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after buying an additional 92,240 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the sale, the director now owns 5,783 shares of the company’s stock, valued at approximately $2,384,215.24. This trade represents a 3.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 113,396 shares of company stock worth $42,175,418. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 6.0 %

UTHR stock opened at $363.25 on Friday. The firm has a market cap of $16.22 billion, a price-to-earnings ratio of 15.95, a PEG ratio of 1.13 and a beta of 0.56. The company’s fifty day simple moving average is $362.93 and its 200 day simple moving average is $328.17. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the previous year, the business earned $5.38 EPS. The firm’s revenue was up 22.9% compared to the same quarter last year. Research analysts expect that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the topic of a number of research reports. Jefferies Financial Group boosted their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.